## ICMJE DISCLOSURE FORM

Date: 26-11-2021	
Your Name: Eric Geijteman	
Manuscript Title: Preventieve	toediening van scopolaminebutyl kan reutelen in de stervensfase voorkomen
Manuscript number (if known):	D6509

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	ZonMw (2016-2020)	Death rattle in the dying phase: is prophylactic treatment effective? (co-applicant)				
Time frame: past 36 months							
2	Grants or contracts from any entity (if not indicated in item #1 above).	SKMS (2021-present)  ZonMw (2021-present)	Advance care planning in hospitals (project leader)  Incentive grant 'resuscitation decisions in Dutch hospitals' (project leader)				
		NWO (2021-present)	Resuscitation decisions in Dutch hospitals (project leader)				

	T		
		Erasmus MC (2021- present)	COVID-19-grant 'efficient use of scarce facilities during pandemics' (co-project leader)
		ZonMw (2020-present)	Prudent medication management in the last phase of life (project leader)
		Erasmus MC Mrace (2020-present)	Towards optimizing anticoagulation therapy in the last phase of life (project leader)
		Horizon2020 (2019- present)	Living well, dying well. A research programme to support living until the end (co-applicant, work package co-leader 'medication review in the last phase of life'
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role	None	
10	in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	

12	12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
S			
13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.